SCHEDULE: 3i LP Updates CNBX Pharma Stake to 9.99%

3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has updated its beneficial ownership in CNBX Pharmaceuticals Inc. to 9.99% through a convertible note.

Summary

• 3i, LP, 3i Management LLC, and Maier Joshua Tarlow collectively report beneficial ownership of 83,595,541 shares of CNBX Pharmaceuticals Inc. common stock.
• This represents 9.99% of the total 753,196,666 shares outstanding as of December 31, 2025.
• The beneficial ownership stems from a senior secured convertible note with a principal amount of approximately $655,924, held directly by 3i, LP.
• Conversion of the note is subject to a 9.99% beneficial ownership limitation provision, preventing ownership from exceeding this threshold.
• The reporting persons share voting and dispositive power over these 83,595,541 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update. It confirms an institutional investor's continued significant, albeit passive, stake in CNBX Pharmaceuticals, which can be seen as a vote of confidence, but offers no new operational insights.

Positives

• A significant institutional investor, 3i, LP, maintains a substantial stake in CNBX Pharmaceuticals Inc., indicating continued interest.
• The existence of a senior secured convertible note provides a financing mechanism for CNBX Pharmaceuticals Inc.

Negatives

• The 9.99% beneficial ownership blocker limits the investor's ability to convert the full note if it would exceed this threshold, potentially capping their upside from conversion.

Risks

• The beneficial ownership is subject to a 9.99% blocker, which could limit the investor's ability to fully convert their note if it would push their ownership above this threshold.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from CNBX Pharmaceuticals Inc. It primarily reports an update to beneficial ownership by an institutional investor.

Management Comments

• The filing of this Amendment No. 7 should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.
• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding more than 5% of a company's stock. For CNBX Pharmaceuticals, a company likely in the biotechnology or pharmaceutical sector, the continued significant stake by 3i, LP, an institutional investor, suggests ongoing confidence or strategic positioning within the company's capital structure, even if passive. This type of filing does not typically provide operational or strategic updates relevant to broader industry trends but confirms investor interest.

Comparison to Industry Standards

• This filing is a standard Schedule 13G amendment, which is a common regulatory disclosure for passive investors exceeding a 5% ownership threshold. There are no specific operational or financial results from CNBX Pharmaceuticals Inc. to compare against industry benchmarks or competitors like Pfizer, Johnson & Johnson, or smaller biotech firms.
• The 9.99% beneficial ownership limitation is a common feature in convertible notes to prevent triggering certain regulatory or corporate governance thresholds, aligning with typical practices for such financing instruments.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception of stability or investor confidence.
• Creditors: The senior secured convertible note indicates a specific debt instrument in the company's capital structure.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by changes in their beneficial ownership.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of passive beneficial ownership and does not contain new material information regarding CNBX Pharmaceuticals Inc.'s operational performance, strategic direction, or financial health. While the continued significant stake by 3i, LP is a neutral to slightly positive signal of investor interest, it does not provide a basis for a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, awaiting more substantive company-specific news or financial results.

Keywords

CNBX Pharmaceuticals, 3i LP, Schedule 13G, Beneficial Ownership, Convertible Note, Equity Stake, SEC Filing, Institutional Investor, Pharmaceuticals